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1. Introduction 
Therapeutic management for ovarian cancer (OC) requires effective treatment methods such 
as optimization in terms of technical variability, dosage, or administration period and the 
introduction of new therapeutic methods in the existing protocols, all in order to improve 
immediate results, especially of the long term. Establishing therapeutic strategies are based 
on the main factors that influence cancer development and prognosis of primary starting 
point of the ovary. Studies have established even a prognostic profile of OC and a profile of 
the degree of response to chemotherapy [Spentzos, 2005]. 
Complex treatment should involve the main therapeutic methods to combat both the 
primary ovarian tumor and secondary determinations: 
- Surgery 
- Chemotherapy 
- Radiation therapy and recently 
- Biological therapy and 
- Hormone 
The main prognostic factor and therapeutic attitude that divides into two different 
directions is the set of FIGO stage of disease. With FIGO, a number of other factors require 
the combination of several methods of therapeutic treatment in the same direction.  
2. Therapeutic strategies in early ovarian cancer 
OC is confined to early stages I-IIa FIGO. In this stage of OC, therapeutic strategies differ 
depending on the presence of several prognostic factors, according to which natural 
evolution of the disease progresses differently. They are represented mainly by: 
- FIGO stage  
- Grading 
- Histology 
- Increased amount of ascites 
- Preoperative or intraoperative tumor intrusion 
- Development of the primary extracapsular tumor 
- Patient age 
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For early stages of OC, Vasey established in 2008 a range of risk depending on the 
therapeutic attitude that fits (Table 1) [Vasey, 2008]. 
 
Good prognosis Medium prognosis Poor prognosis 
Stage Ia 
Grade 1 
Optimal Staging 
CA125 ≤ 130 
Stage Ib 
Grade 2 
Suboptimal staging 
Stage Ic 
Grade 3 
Biopsy only 
Pre-op rupture 
Aneuploidy 
Table 1. Range in early OC [Vasey-2008]. 
However, Virgote considered the main prognostic factor tumor grading in tumor recurrence 
risk, followed in order by preoperative tumor, intraoperative tumor rupture, namely age 
[Vergote, 2001]. 
2.1 Radiation 
Radiotherapy, either whole abdomen teletherapy or intraperitoneal with 32P brachytherapy 
is a method that initially had similar results with combined-modality therapy (CMT), when 
it was not done with chemotherapy based on platinum ions. Lately it was abandoned due to 
inferior results and increased risk to platinum-based CMT, in which the rate of major 
complications locally was increased. Thus, these procedures are currently strict historical 
interest method [Vergote, 1992; Young, 2003]. 
2.2 Surgery 
OC surgery for early stages follow both the primary tumor, complete excision to the limits 
cancer and dissemination in the main sires, to their excision or biopsy of their evaluation by 
sampling [Zoung, 1983; Cass, 2001]. 
Surgery methods are the following: 
- Abdominal hysterectomy with bilateral anexectomy by median approach 
- Total omentectomy 
- Biopsy pelvic peritoneum (a Pap smear test form the peritoneum fragments from 
diaphragm is accepted as an alternative method) [Chhieng, 2011].  
- Sampling bilateral pelvic and paraaortic lymph nodes  
- Lavage cytology of peritoneal cavity 
- Appendectomy in all patients with OC epithelial origin, especially if they have 
mucinous histology or clear cell [Ozols, 2005]. 
Controversy and debate regarding surgery has occurred for the patients came seeking 
preservation of reproductive function in these stages. Conservative surgery consisting of 
unilateral anexectomy is accepted as a therapeutic method in young patients with OC in 
first stage, with favorable histological structure (low malignant potential, stromal tumors, 
germinomas) and seeking fertility preservation [Ozols, 2005]. Literature data for carefully 
and properly selected cases, do not report an increased risk of relapse, or a lower survival 
rate in patients treated conservatively compared to those treated aggressively [Young, 2003]. 
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If the inspection is suspecting lesion on contralateral ovary in patients treated conservatively, 
surgical treatment, in addition to unilateral anexectomy should be supplemented by targeted 
biopsy of suspicious areas [Ozols, 2005]. The presence of tight adhesions between adjacent 
organs and regional annexes requires the overstaging and the right therapy approach by 
aggressive surgery and the introduction of adjuvant chemotherapy [Ozols, 2005]. Minimally 
invasive approach to OC (laparoscopic or robotic) is a therapeutic method that tends to win 
ever more ground in early stages of OC. Larger studies are needed to analyze the laparoscopic 
approach compared to the staging and treatment of early OC [Medeiros, 2011]. For patients 
with favorable prognostic factors (std. Ia, Ib, G1) surgery is considered sufficient as the only 
therapeutic approach without requiring the association of adjuvant chemotherapy [Young, 
2003]. For patients with moderate (std. Ib, G2, suboptimal staging), or with poor prognostic 
factors (std. Ic, IIa, G3, clear cell carcinoma, close adhesions, break tumor near the operation) 
surgery is insufficient, requiring adjuvant CMT compulsory association as a therapy method 
complementary to the management of these cases [Trimbos, 2003]. 
2.3 Chemotherapy 
Chemotherapy as an adjuvant in the treatment protocol of early OC has always been an 
issue that concerns the role and selection of cases where its use proves its real efficiency in 
terms of median progression-free survival (PFS) and especially overall survival (OS). The 
controversies about the application of OC in the early stages CMT year refer specifically to: 
- The group of patients to be associated 
- Type of CMT and the timing  
- Regimens (monotherapy/polytherapy) 
- The administration (number of series) 
Initially addressed to the patients with the increased prognostic risk groups of early OC, the 
indication of the application of CMT was extended to patients with moderate risk group due 
to significant differences in overall survival and median progression-free survival [Young, 
2003]. Regarding the timing of CMT in patients with early OC, both technically and as a 
result, CMT is totally adjuvant; its administration is in fact a therapy nonsense, which would 
require an initial biopsy laparatomy for a resectable case in radical limits. As an 
extrapolation of the results obtained with different regimens applied to patients with 
advanced OC, it was concluded that the most effective combination therapy is the combined 
protocol Carboplatin AUC 5 to 7.5 mg/ml/min + Paclitaxel 175mg/m2/3h [Kyrgiou, 2006]. 
Some studies that compared adjuvant CMT versus "watchful waiting”, established that the 
use of adjuvant CMT improves OS and PFS in high-risk patients with early stages of OC. 
This was confirmed recently by a metanalysis comprising five prospective randomized 
studies. Its final conclusion was that the patients who received platinum-based adjuvant 
chemotherapy had better OS [hazard ratio (HR) 0.71, 95% confidence interval (CI) 0.53-0.93] 
and PFS (HR 0.67, 95% CI 0.53- 0.84) than patients who did not receive treatment adjuvant 
[Colombo, 2010]. One of the conclusions of mentioned metanalysis surprised by considering 
early adjuvant CMT as a factor influencing the final results in OC, but was very important in 
the further development of specific cases and suboptimal staging. Later was observed that 
two thirds of the studies that classified patients of having early stages OC, could classified 
that patients in higher stages. In these cases there was a significant difference in OS and PFS 
terms considering association or not adjuvant CMT at initial surgery resection. However, in 
www.intechopen.com
 
Ovarian Cancer – Clinical and Therapeutic Perspectives 
 
132 
suboptimal staged group with unfavorable prognostic factors, adjuvant CMT could address 
and properly stage the group of patients [Trimbos, 2003]. The controversy regarding the 
duration of the adjuvant CMT tried to be clarified in GOG-157 study which demonstrated 
that 6 cycles of Carboplatin + Paclitaxel have the same therapeutic effect (OS and PFS) with 
only 3 cycles with the same combination, but only with an increased cumulative toxicity 
[Bell, 2003]. A 33 percent reduction in the risk of loco-regional relapse, demonstrated using 
the same 6-cycle regimens, compared with 3 cycles, led to the routine use of CMT under 
standard adjuvant 6 cycles [Bell, 2003].  
3. Therapeutic strategies in advanced ovarian cancer 
There is a significant difference between the management of early stages and advanced 
stages of OC management and the latter, there is a difference between stages II B - III C, 
respectively, stage IV. The inclusion of stage II was made considering prognosis of patients 
with OC at this stage, and data showed that are closer to those of stage III. For stage II B - III 
C of OC, therapeutic methods are represented by chemotherapy and surgery, radiotherapy 
with more historical significance and biological therapy. 
3.1 Radiation 
Radiotherapy (either WAR or intraperitoneal brachytherapy) was analyzed in several 
studies, the last completed in 2003. The studies have underlined the utility of this method 
but also the increased risks of major complications [Verheijen, 2006]. 
3.2 Surgery 
In the early stages of OC, surgery proposed a radical intervention intended to remove the 
entire tumor, on the one hand, and to estimate the peritoneal dissemination of cancer in any 
sites for a more accurate staging, on the other hand. In advanced stages, cytoreductive 
surgery (CRS) has the main purpose not to excise the whole tumor, but to obtain a small 
volume of residue lesions. Direct proportionality between the individual and the extent of 
cytoreduction evolution was demonstrated by multiple studies. In 2002, Bristov even 
proposed a mathematical model, showing that the ultimate goal of surgery is to obtain 
under 1 cm of residual tumor, which can involve, if feasible, multivisceral resections, 
peritonectomy, stripping diaphragm, pelvic radical dissection, splenectomy [Marszalek, 
2010]. A review on the subject showed an increased OS from 17 to 39 months [Bristow, 
2002]. Discussions regarding aggressive surgical risk refer to the degree that is vital for the 
patient. Thus, if the patient is suitable for CRS at primary laparatomy, then the biopsy is 
followed by neoadjuvant CMT and subsequently secondary CRS [Tangjitgamol, 2010]. It is 
preferable that secondary CRS be performed after three cycles of CMT and be followed by 
three cycles of adjuvant with the same regimen CMT. In patients with complete response to 
treatment, a second look surgery has not proven be beneficial of the OS. Secondary CRS 
scheduled after neoadjuvant CMT does not show a clear increased of OS [Winter, 2008]. 
3.3 Chemotherapy 
Chemotherapy is a mandatory means in the treatment of advanced OC. Over time there 
have been many controversies concerning: 
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- When administered CMT 
- Therapeutic regimes 
- Simultaneous therapy versus sequential therapy 
- Duration of therapy (no. of cycles) 
- Route of administration 
- Tumor residue 
3.3.1 Timing CMT 
The debate is limited not only about using CMT as adjuvant, but also about the possibility of 
its association as neoadjuvant therapy. Administration of preoperative CMT (preferably 3 
cycles) has proven useful only in cases where primary optimal CRS surgery was impossible 
to perform, and response to treatment favorable, allowing a secondary CRS [Vergote, 2010]. 
Survival, however, in these cases proved to be a less than optimal in primary CRS cases 
followed by adjuvant CMT [Kumar, 2010]. The remaining cases that could benefit from 
primary CRS will receive mandatory six cycles of adjuvant CMT 3 weeks each. 
3.3.2 Regimens 
Since 1996 it was formulated the standard scheme for CMT in advanced OC, combination of 
platinum and taxane ions, causing abandonment included Cyclofosfamide regimens, 
doxorubicin or 5-fluorouracil [McGuire, 1996]. The response rates to this combination in 
patients with advanced OC were different, depending on the degree of primary CRS: 70% 
for suboptimal CRS and over 80% for primary optimal CRS [Ozols, 2003].  
Usefulness of paclitaxel-based chemotherapy potentiation of platinum ions was 
demonstrated in Gynecologic Oncology Group (GOG) 111 study and European-Canadian 
(OV-10) trial, but it has not been confirmed by following studies: The Third International 
Collaborative Ovarian Neoplasm Study (ICON-3) and GOG 132 [McGuire, 1996; Stuart, 
1998; Muggia, 2000]. GOG 114 study underlines the effectiveness of carboplatin and 
cisplatin same regimes combined with a top low toxicity for carboplatin [Ozols, 2003]. In 
combination with paclitaxel chemotherapy comparing the study above demonstrates 
increased efficiency of carboplatin in terms of OS and PFS. This is another argument in 
favor of regime 7.5 Carboplatin/Paclitaxel 175 mg/m2/3h, as concluded in GOG 158 
study [Ozols, 2003]. 
3.3.3 Simultaneous versus sequential therapy 
Sequential administration of cytostatics in combination regimens is also an important 
controversy in the treatment of advanced OC. In GOG-132 study and The European-
Canadian study, one of the conclusions was that the benefit of platinum ions taxane 
association is found both in the system simultaneously, and in the sequence [Vermorken, 
2000, Piccart, 2000]. In GOG 132 study was also demonstrated that OS was similar in 
regimens combined platinum + taxane type ions, regardless of the combination 
simultaneously, or sequentially, resulting less encouraging for monotherapy (regimes 
based exclusively platinum ions showing a 5-year OS 67%). The weakest cytostatic agent 
used as monotherapy was paclitaxel (exclusive regimes showing a 5-year OS 42%) 
[Vermorken, 2000; Muggia, 2000]. 
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Trial and Randomization 
Patient 
Number
Stage CCR (%)
Median PFS 
(months)
Median OS 
(months) 
GOG-111 386 III, IV  
Paclitaxel (135 mg/m2) 51 18 38 
Cisplatin (75 mg/m2) P = .0002 P = .0001 
Cyclosphosphamide 
(750 mg/m2) 
  31 13 24 
Cisplatin (75 mg/m2)
OV10  
668 IIB IV    
Paclitaxel (175 mg/m2) 50 16 35 
Cisplatin (75 mg/m2) P = .0005 P = .0016 
Cyclophosphamide (750 mg/m2) 36 12 25 
Cisplatin (75 mg/m2)
ICON-3 
2074 Ia IV    
Paclitaxel (175 mg/m2) NA 17.3 36.1 
Carboplatin (AUC 5 to 6) P = .19 P = .74 
Carboplatin (AUC 5 to 6) NA 16.1 35.4a 
Cisplatin (50 mg/m2)
Doxorubicin (50 mg/m2) 
Cyclophosphamide (500 mg/m2)
     
GOG-132 614 III IV  
Paclitaxel (135 mg/m2) NA 16 35b 
Cisplatin (75 mg/m2)  
Cisplatin (100 mg/m2) NA 16.4 30.2 
Paclitaxel (200 mg/m2) NA 11.4 26 
Table 2. Randomized Trials of Paclitaxel versus Non-Paclitaxel First-Line Therapy in 
Advanced Epithelial Ovarian Cancer [De Vita, 2008]. 
3.3.4 Duration of therapy (number of cycles) 
Three randomized trials that analyzed the effectiveness of increasing the number of cycles of 
CMT on the OS have concluded unanimously that the results are similar, but increased the 
frequency of complications (especially neurological). The cumulative toxicity was directly 
proportional with the number of cycles. It was established that the optimal number of cycles 
is 6, each separated by 3 weeks of rest between them [Colombo, 2010]. 
3.3.5 Route of administration 
Until recently, the route of administration of the CMT was systemic intravenous peripheral 
or central. Increasing concentration in the peritoneal cavity of CMT after primary CRS, 
without causing systemic side effects, is believed to be a result of the ratio of cisplatin, 
paclitaxel, respectively, between the peritoneum and systemic circulation central. Since then, 
it appeared the idea of intraperitoneal CMT [Rothenberg, 2003]. Since 1980 analyzed in 
numerous randomized trials, intraperitoneal administration of CMT was shown to improve 
OS and PFS in optimal cytoreduced patients and in terms of pathological complete 
remission in patients in whom cytoreduction was actually, suboptimal (residual tumor < 2 
cm was accepted as optimal at that time), compared with only intravenous administration of 
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CMT [Alberts, 1987]. GOG-172 (Armstrong, 2006) study pointed out that the combination of 
CMT to the intravenous intraperitoneal resulting OS rise from 49.7 to 65.6 months (35%) and 
PFS from 19 to 24 months (with 26%), but with a greatly increased associated toxicity. In 
58% of cases resulted the abandonment of intraperitoneal administration of CMT, making 
only 42% complete the 6 cycles (given on day 2 and day 8). Cochrane's metanalysis, 
balancing risks and benefits, reported in eight randomized trials of systemic administration 
of CMT (intraperitoneal association and administration) concluded that effect is beneficial in 
terms of OS (hazard ratio 0.799) and PFS (hazard ratio 0.792) [Jaaback, 2006]. Despite these 
favorable results, many authors have remained skeptical about this therapy, which was still 
considered at an experimental level [Gore, 2006; Ozols, 2006]. Since 1994, the efficiency of 
intraperitoneal CMT is questioned, by administering in hyperthermia. In this respect, there 
were a lot series of studies that examined the usefulness of this method in the management 
of OC. CMT administration at 39 to 44,5 degrees Celsius, in addition to increased 
locoregional and systemic toxic effect, translated into a major complication rate of 28.3% 
[Ryu, 2004] and a perioperative mortality of 3.7% [Gori, 2005]. 
HIPEC indications can be summarized in: 
- Recurrent or persistent disease: the use of intraperitoneal CMT extended the period of 
progression of OC lesion from 10 to 21.8 months [Zanon, 2004; Helm, 2007]. 
- As first-line therapy: although logical, it is recommended an aggressive approach of OC, 
but when it was applied, the number of cases was too small for a conclusion [Piso, 2004]. 
- When CRS is scheduled after neoadjuvant CMT, it is preferably an optimal 
cytoreduction followed by HIPEC. The number of cases remained was insufficient to 
have a clear conclusion [Reichman, 2005; Yoshida, 2005]. 
- CMT as consolidation therapy, when it is applicable second look surgery or after a 
partial response in these cases.  
One study observed an improvement from 19.8 to 48.7 months and OS of 52, 8 to 63.4 
months (Ryu - cisplatin + interferon treatment) [Ryu, 2004]. These results are relative, since, 
although in large numbers, the patients from this study were not homogeneous in terms of 
progress including early cases. Another study obtained a recurrence rate of 69.9% for HIPEC 
compared with 63.1% in the control group, a difference of OS from 64.4 to 46.4 months, but 
proved to be insignificant (p = 0.29), due to lots of inhomogeneity [Gori, 2005]. 
Several ways to amend the standard treatment protocols were tried in order that adjuvant 
CMT to increase: 
- Addition of the third chemotherapy 
- Management of locoregional chemotherapy 
- Maintenance Chemotherapy 
- Increasing doses 
- The combination of biological therapy 
GOG-111 and OV-10 studies identified the need to improve therapeutic strategies 
considering long-term adverse outcomes [McGuire, 1996; Stuart, 1998].  
Combination of the third drug 
The combination of the third drug joins the regimen used to treat OC (Carboplatin - 
Paclitacsel). Other chemotherapy gemcitabine Dacsil, topotecan achieved an improvement 
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of the OS or PFS, but with a toxicity increased as studies ICON-5 and GOG 182 have shown. 
The role of the third combination chemotherapy was relevant for mucinous adenocarcinoma 
OC type or clear cell [Bookman, 2006]. 
Locoregional administration of CMT 
Results of studies on intraperitoneal chemotherapy have been mentioned previously. 
Increasing doses of CMT 
The concept of increasing doses of CMT has been divided in two: on the one hand, the 
concept of increasing the dose (increasing the effective dose per chemotherapy cures the 
same secventiality) and, on the other hand, the concept of dose densification (the same dose 
in more frequent cycles). Increasing the desired effect by increasing the dose of 
chemotherapy was ruled out by the study AGO-Ovar/AIO and EBMT in 2007. The study 
showed that there were no significant differences in OS and PFS terms [Mobus, 2007]. In 
2008, Isonishi and collaborators demonstrated, however, through a study on 631 patients 
randomized, that in the second year, OS and PFS are significantly influenced (77.7 versus 
83.6, respectively 17.1 versus 27.9) after the densification of Carboplatin dosage scheme - 
Paclitaxel, when these were administered weekly [Ionishi, 2008]. 
Maintenance therapy 
The maintenance therapy requires long term administration, after six cycles of combined 
CMT or variable number of cycles of CMT administered as monotherapy. Most studies that 
examined the maintenance therapy with ions of platinum, taxanes, topotecan, epirubicin, 
surprised no significant differences in OS and PFS terms. One study reported that 
maintenance therapy for 12 months with Paclitaxel 7 months improved PFS [Markman, 
2003; Markman, 2009]. 
4. Therapeutic strategies in recurrent ovarian cancer 
Patients that experienced disease relapse or are refractory to first-line treatment are 
candidates for second-line chemotherapy. An ideal agent will provide broad antitumor 
activity, demonstrate a favorable toxicity profile, and have generally convenient 
administration, among other factors. Additionally, many of the more active agents used in 
second-line treatment (e.g., gemcitabine, liposomal doxorubicin, and topotecan) are non–
cross-resistant to first-line therapies. They exhibit novel mechanisms of action relative to 
cisplatin/carboplatin and paclitaxel, thereby targeting a different aspect of cell division. The 
agents include members of the platinum and taxane families, such as carboplatin and 
paclitaxel (every 3 weeks and weekly schedules), respectively; the topoisomerase I inhibitor 
topotecan; the liposome-encapsulated anthracycline doxorubicin (liposomal doxorubicin); 
and the novel antimetabolite gemcitabine. The clinical utility (benefit-risk ratio) of these 
agents in the recurrent ovarian cancer setting will be reviewed briefly below. 
Hexamethylmelamine 
Hexamethylmelamine (altretamine; Hexalen; MGI Pharma, Bloomington, MN) is an 
approved single-agent therapy for ovarian cancer. It has the advantage of oral 
administration, which may be preferable for some patients. However, it has been 
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demonstrated only limited activity in patients with relapsed platinum-refractory ovarian 
cancer [Markman, 2003]. 
Platinum 
Patients that were found to be platinum sensitive at first-line therapy are likely to benefit 
from reintroduction of platinum on disease recurrence. Both cisplatin (Platinol; Bristol-
Myers Squibb, Princeton, NJ) and carboplatin (Paraplatin; Bristol-Myers Squibb) are FDA-
approved for the treatment of recurrent ovarian cancer and are often used as monotherapy 
or in combination with paclitaxel. Carboplatin is considerably less nephrotoxic than 
cisplatin; however, because the primary route of clearance is renal, the potential for acute 
renal toxicity should be monitored when it is established the dosage. In clinical trials of 
single-agent carboplatin, overall tumor response rates ranged from 21% to 30% in platinum-
resistant or platinum-refractory patients and from 27% to 53% in platinum-sensitive 
patients [Williams, 1992; Kavanagh J, 1995; Bolis G, 2001]. Furthermore, the proportion of 
patients with stable disease was approximately 18% to 33%. 
Gemcitabine plus Platinum 
Gemcitabine (Gemzar; Eli Lilly and Co., Indianapolis, IN) has received approval in other 
indications but is still investigational in the treatment of ovarian cancer. Gemcitabine can be 
safely combined with carboplatin for the treatment of patients with relapsed ovarian 
cancer [du Bois, 1995]. The gemcitabine plus carboplatin regimen recently compared 
favorably with carboplatin alone in a randomized trial in patients with relapsed platinum-
sensitive ovarian cancer, producing significant improvements in quality of life, significantly 
faster palliation of abdominal symptoms, significant improvements in response rate, and a 
significant increase in progression-free survival. 
Paqclitaxel 
 Every three weeks  
Paclitaxel (Taxol; Bristol-Myers Squibb) is indicated as first-line (with cisplatin or 
carboplatin) and subsequent therapy for the treatment of ovarian cancer. The taxane is 
administered in two different schedules; however, the FDA-approved dosing is intravenous 
administration over 3 or 24 hours once every 3 weeks. In studies of paclitaxel administered 
on this schedule, overall tumor response rates were approximately 22% in platinum-
resistant or platinum-refractory patients and 45% in platinum-sensitive patients [Cantu 
2002; Gore, 1995; Trimble, 1993]. Median survival in platinum-resistant or refractory 
patients ranged from 6 to 9 months and was 26 months in 47 evaluable platinum-sensitive 
patients is generally less favorable than it is when the agent is administered weekly; 
therefore, partly because of the sometimes debilitating toxicity associated with the approved 
schedule, investigators have developed interest in evaluating the antitumor activity and 
tolerability of weekly schedules. 
 Weekly 
Although weekly paclitaxel is not an approved regimen in ovarian cancer therapy, overall 
tumor responses were at least comparable and potentially higher than those achieved with 
the every-3-week’s schedule in preliminary studies in patients with recurrent 
disease [Rosenberg, 2002]. 
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Platinum plus paclitaxel 
Patients who responded to combination first-line therapy may benefit from reintroduction 
of platinum and paclitaxel on disease recurrence. In the largest study to date conducted in 
collaboration with the International Collaborative Ovarian Neoplasm (ICON4) and three 
cooperative groups, 802 relapsed patients with ovarian cancer were randomized to 
treatment with platinum plus a taxane or single-agent platinum [Parmar, 2003] . Overall 
tumor response rate in the combination group was 66% compared with 54% in the platinum 
treatment group (P = 0.06). Notably, the hazard ratios for progression-free survival and 
overall survival were 0.76 and 0.82, respectively, favoring platinum plus paclitaxel over 
single-agent platinum in both cases. Thus, there was a statistically significant difference in 
survival favoring the platinum plus paclitaxel combination compared with single-agent 
platinum (P = 0.023) [Parmar, 2003]. 
Topotecan 
Topotecan (Hycamtin; GlaxoSmithKline, Philadelphia, PA) is an active and well-established 
agent currently indicated [topotecan (1.5 mg/m2) on days 1 through 5 of a 21-day cycle] for 
the treatment of relapsed metastatic ovarian cancer after failure of initial or subsequent 
chemotherapy. 
Docetaxel 
Although docetaxel (Taxotere; Aventis Pharmaceuticals Inc., Bridgewater, NJ) is more 
commonly used in the treatment of non–small-cell lung cancer and breast cancer, recent 
studies have been conducted in patients with relapsed ovarian cancer [Rose, 2003; 
Markman, 2003]. In the largest study, with 60 paclitaxel-resistant ovarian cancer patients 
receiving docetaxel (100 mg/m2) every 21 days, Rose and collaborators reported a 
response rate of 22%, including 5% and 17% complete and partial response rates, 
respectively [Rose, 2003]. 
Gemcitabine 
Although is not currently FDA-approved for the treatment of ovarian cancer, gemcitabine 
(Gemzar; Eli Lilly and Co.) has typically been administered as monotherapy in pretreated 
patients with ovarian cancer. 
Etoposide 
Etoposide (VePesid; Bristol-Myers Squibb) inhibits topoisomerase II and thus inhibits DNA 
synthesis. In a phase II study in patients with recurrent ovarian cancer investigated 
etoposide (150 mg/m2) on days 1 through 3 of a 28-day cycle [Eckhardt, 1990]. Of the 71 
patients evaluable for response, 1 achieved a complete response, and 5 achieved a partial 
response. An additional 48 patients had stable disease. 
5. Conclusions 
The questions of optimal treatment duration and whether patients should receive treatment 
to disease progression remain unanswered. However, in the absence of definitive evidence 
addressing optimal treatment duration in patients with relapsed disease, it should be 
recognized and appreciated that a number of agents are available that offer a level of 
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flexibility and treatment customization heretofore unseen in the management of recurrent 
ovarian cancer in this generally poor-prognosis patient population. These agents should be 
wielded with the critical goal of balancing the efficacy and toxicity of particular agents and 
schedules with their effect on symptoms and quality of life. 
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